<DOC>
	<DOCNO>NCT00462202</DOCNO>
	<brief_summary>The purpose study assess tolerability safety KRX-101 treating persistent microalbuminuria type 2 diabetic patient also treat stable , maximum tolerated dos either ACE inhibitor A2 receptor blocker .</brief_summary>
	<brief_title>Open Label Tolerability Safety Study KRX-101 Australia , New Zealand , Hong Kong</brief_title>
	<detailed_description>Diabetes one common cause end-stage renal disease ( ESRD ) U.S. many develop nation . Despite advance clinical care , include improvement glycemic blood pressure control , number new case diabetes-related ESRD continue rise , especially patient type 2 diabetes . The current standard care prevention treatment diabetic renal disease include screen diabetic patient microalbuminuria . Patients test positive microalbuminuria treat either ACE inhibitor A2 receptor blocker . Both class medication show reduce level microalbuminuria patient population . This improvement microalbuminuria also show delay progression number renal function problem , well minimal delay certain clinical event include ESRD . Unfortunately , patient achieve majority therapeutic effect ACE inhibitor A2 receptor blocker within first 6 month therapy , many patient continue show persistent microalbuminuria . Therefore , patient increase risk progress ESRD due lack adequate benefit current medication . Microalbuminuria straight-line relationship adverse renal outcome ; therefore level reduction may clinical benefit . It reasonable believe patient reduce complete remission microalbuminuria may also lessen risk progress ESRD . Thus , KRX-101 able cause reduction complete remission microalbuminuria normoalbuminuria , patient may receive significant clinical benefit .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>At least 18 year age successfully complete Keryx Study 101301 . Diagnosis DM2 base ADA criterion . Continued stable seat systolic blood pressure &lt; 150 mmHg diastolic blood pressure &lt; 90 mmHg . Provide write informed consent participate study . If female childbearing potential , must continue willing use adequate contraception , determine investigator , duration study . Evidence hepatic dysfunction include total bilirubin &gt; 2.0 mg/dL ( 34 micromol/L ) liver enzymes &gt; 3 time upper limit normal . Unstable angina pectoris New York Heart Association Class III IV congestive heart failure . A history major medical condition , include limited : aortic aneurysm ; myocardial infarction , stroke , cardiovascular event past 3 month ; gastrointestinal bleeding past 3 month ; HIV ; medical condition deem serious investigator . Active Hepatitis B C ( currently active disease define abnormal liver biopsy persistent , elevated transaminase , SGOT , SGPT ) . Any risk bleeding , include history bleed diathesis platelet count &lt; 100,000/mmÂ³ . Active metastatic cancer ( note : superficial basal carcinoma skin exclusion ) . Anticipated surgery within trial period . History noncompliance medical regimen Keryx Study No.101301 . Participation experimental drug study past 60 day , except KRX101301 , prior entry study , plan participate experimental drug study study period . Lactation , pregnancy , anticipate planned pregnancy study period . Known allergy intolerance heparinlike compound . Patients specific renal disease know cause nephropathy , patient specific , clinically significant renal disease . Inability give inform consent cooperate study personnel .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Microalbuminuria</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>KRX-101</keyword>
	<keyword>Sulodexide</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>Keryx</keyword>
	<keyword>Collaborative Study Group</keyword>
	<keyword>Diabetic nephropathy persistent microalbuminuria</keyword>
</DOC>